Saturday 17 October 2026
Export SIGA’s income statement to Excel — free account
Siga Technologies Inc.
SIGA Healthcare Drug Manufacturers Specialty & Generic
Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024. In the quarter to June 2026, revenue fell 49.5%, EPS fell 66.0% and free cash flow fell 76.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
3.17
0.02
−0.63%
Follow SIGA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 18.45 | 18.28 | 8.85 |
+8 more quarters Free account |
P/S ratio |
4.87 | 4.09 | 4.62 | 3.80 | |
P/FCF ratio |
0.00 | 13.99 | 10.14 | 5.63 | |
P/Operating CF |
17.21 | (44.24) | (25.92) | (66.76) | |
P/B ratio |
1.58 | 2.53 | 2.20 | 3.22 | |
Price to Tangible BV |
1.59 | 2.54 | 2.21 | 3.23 | |
EV/Sales |
5.64 | 4.23 | 4.66 | 3.73 | |
EV/EBITDA |
0.00 | 18.70 | 18.18 | 7.07 | |
EV/Operating CF |
(15.00) | 14.30 | 10.15 | 5.51 | |
EV/FCF |
(14.74) | 14.48 | 10.23 | 5.52 | |
Quick Ratio |
15.90 | 2.30 | 8.79 | 7.02 | |
Current Ratio |
21.72 | 3.25 | 11.83 | 9.17 | |
Net Debt/EBITDA |
(8.36) | 28.15 | 16.57 | 17.06 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.26 | 0.40 | 0.41 | 0.81 | |
Operating CF/Net income |
1.22 | 2.51 | 3.11 | 1.54 | |
Capex/Depreciation |
0.00 | 0.00 | (0.28) | (2.04) | |
Research and Development Expense of Revenue |
10.70% | 63.27% | 132.87% | 269.24% | |
Selling, General and Administrative Expense of Revenue |
12.56% | 74.86% | 138.71% | 182.69% | |
Intangible Assets out of Total Assets |
0.01 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2.95% | 12.06% | 20.36% | 29.55% | |
Graham Net Nets |
0.61 | 0.38 | 0.44 | 0.30 | |
Graham Number |
0.00 | 3.72 | 4.57 | 8.13 | |
Earnings Yield |
(1.10%) | 5.42% | 5.47% | 11.30% | |
Free Cash Flow Yield |
(7.86%) | 7.15% | 9.87% | 17.75% | |
Revenue per Share |
0.57 | 0.09 | 0.05 | 0.04 | |
Operating CF per Share |
0.21 | (0.12) | (0.24) | (0.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.21 | (0.12) | (0.24) | (0.14) | |
Cash per Share |
1.64 | 2.03 | 2.17 | 2.40 | |
Shareholders Equity per Share |
2.30 | 2.12 | 2.78 | 2.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.30 | 2.12 | 2.78 | 2.84 | |
Free Cash Flow |
15.17 | (8.66) | (16.90) | (10.10) | |
Working Capital |
162.53 | 146.37 | 194.86 | 202.90 | |
Capital Expenditures |
— | — | (0.04) | (0.29) | |
Net Current Asset Value |
159.93 | 143.76 | 192.21 | 199.62 | |
EV/EBIT |
0.00 | 19.22 | 18.61 | 7.11 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.11 | |
Price to Operating Income |
0.00 | 18.58 | 18.44 | 7.26 | |
| Other line items | |||||
Average Receivables |
6.83 | 5.84 | 12.21 | 7.29 | |
Average Payables |
1.05 | 3.77 | 1.08 | 3.15 | |
Average Inventory |
38.36 | 57.78 | 49.31 | 55.02 | |
Average Assets |
205.53 | 233.23 | 231.90 | 213.48 | |
Average Common Equity |
187.30 | 183.88 | 207.31 | 186.46 |
Columns are period end dates